Anti-STEAP1 T-Cell Redirecting Antibody for Targeted Tumor Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatment options for prostate cancer, such as surgery and radiation therapy, come with significant side effects, and there is a need for alternative antibody-based therapeutic options that effectively target prostate cancer-specific antigens like STEAP1 without adverse impacts on patient quality of life.
Innovation Solution
Development of an antigen-binding protein that specifically binds to STEAP1, comprising specific variable heavy and light domains with defined CDR sequences, and a heterodimeric antibody format that includes a scFv covalently attached between the CH1 and Fc domains, capable of redirecting T-cell cytotoxicity to prostate cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-Steap1 antibodies are used for therapeutic purposes, then tumor cell killing activity is improved, but off-target effects on healthy tissues may occur
Solution Approach 1:
The patent applies local quality by creating antigen-binding proteins with highly specific binding characteristics tailored to recognize Steap1 on tumor cells. The proteins are engineered to have optimized binding affinity and specificity parameters, ensuring they interact preferentially with tumor cell targets while minimizing cross-reactivity with healthy tissues. This localized optimization of binding properties at the molecular level resolves the contradiction between effective tumor killing and avoiding off-target effects.
2Ease of manufacture
If conventional antibodies are used, then manufacturing complexity is reduced, but affinity maturation and humanization are time-consuming
Solution Approach 1:
The patent employs preliminary action by pre-engineering antigen-binding proteins with optimized binding characteristics through rational design and selection methods. Instead of performing time-consuming affinity maturation steps after antibody production, the invention performs affinity optimization during the protein design and selection phase using phage display libraries and selective binding assays. This preliminary optimization of binding affinity and specificity accelerates the overall development timeline while maintaining manufacturability.
3Measurement precision
If early-stage cancer detection methods are used, then diagnostic accuracy is improved, but sensitivity for early-stage cancers is insufficient
Solution Approach 1:
The patent applies parameter changes by developing antigen-binding proteins with dramatically enhanced binding affinity for Steap1, achieving equilibrium dissociation constants (Kd) in the low picomolar to high femtomolar range. This parameter optimization of binding strength enables the detection of极低 concentrations of tumor cells and circulating tumor cells, thereby improving sensitivity for early-stage cancer detection while maintaining diagnostic accuracy through specific recognition of the Steap1 antigen.
Data Source
Figure 1~3
Figure 4A
Figure 4B
AI summary
The disclosure provides novel antigen-binding proteins that bind STEAP1 and methods of use.